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Neurobiology of Disease

Glucocorticoid Protection of Oligodendrocytes against
Excitotoxin Involving Hypoxia-Inducible Factor-1␣ in a
Cell-Type-Specific Manner
Yu-Yo Sun,1,2 Chen-Yu Wang,1 Ming-Feng Hsu,6,7 Shu-Hui Juan,1,2 Chiu-Yun Chang,3 Chih-Ming Chou,4
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Glucocorticoids are commonly used in treating diseases with white matter lesions, including demyelinating diseases and spinal cord
injury (SCI). However, glucocorticoids are ineffective in gray matter injuries, such as head injury and stroke. The differential glucocorticoid effects in white and gray matter injuries are unclear. We report here a novel mechanism of methylprednisolone (MP), a synthetic
glucocorticoid widely used for treating multiple sclerosis and SCI, in protecting oligodendrocytes (OLGs) against AMPA-induced excitotoxicity, which has been implicated in the white matter injuries and diseases. The cytoprotective action of MP in OLGs is causally related
to its upregulation of a neuroprotective cytokine erythropoietin (Epo). MP transactivation of Epo expression involves dual transcription
factors: glucocorticoid receptor (GR) and hypoxia-inducible factor-1␣ (HIF-1␣). Coimmunoprecipitation, chromatin immunoprecipitation analysis, yeast two-hybrid analysis, and structure modeling of three-dimensional protein–protein interactions confirm that MP
induces interaction between GR DNA binding domain and HIF-1␣ PAS domain, with subsequent recruitment of HIF-1␤ to transactivate
Epo expression in OLGs. In contrast, MP activates GR but does not induce GR–HIF-1␣ interaction, HIF-1␣ binding to Epo enhancer/
promoter, or Epo expression in cultured cortical neurons. The OLG-specific GR–HIF-1␣ transactivation of Epo provides novel insights
into the development of more effective therapies for diseases affecting the white matter.

Introduction
Neuroprotective strategies for treating CNS disorders have been
directed mostly at preserving gray matter or neurons (Lipton,
2006). However, white matter injuries, as seen in demyelinating
diseases, including multiple sclerosis (MS) and spinal cord injury
(SCI), may have an even greater impact on functional outcomes
(Bradbury et al., 2002; Stys and Lipton, 2007). For example, disability after SCI is primarily caused by the white matter lesion
(Wrathall et al., 1994; Crowe et al., 1997). Gray matter injury,
sparing most white matter (e.g., central cord syndrome), results
in segmental motor/sensory dysfunction. Disability after SCI can
be mostly ascribed to injury to the white matter, which contains
the long tracts. Death of oligodendrocytes (OLGs), which form
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myelin sheath and maintain long tract function in the CNS, is a
prominent pathological feature in demyelinating diseases and
SCI (Crowe et al., 1997; Miller and Mi, 2007). OLG death in these
disorders results, in part, from excitotoxicity involving AMPA
receptor (McDonald et al., 1998; Smith et al., 2000; Miller and Mi,
2007). AMPA receptor antagonism is effective in salvaging white
matter after traumatic or ischemic SCI (Wrathall et al., 1994;
Kanellopoulos et al., 2000).
Glucocorticoids (GCs), primarily methylprednisolone (MP), are
the mainstay in treating patients with diseases affecting the white
matter, including MS and SCI (Bracken et al., 1990; Zivadinov et al.,
2001; Chataway et al., 2006). GCs regulate transcriptional events by
activating glucocorticoid receptor (GR), which binds to glucocorticoid response element (GRE) or interacts with other
transcription factors to regulate gene expression (Becker et al.,
1986). GR modulation of inflammatory/immune or oxidative
processes are the proposed mechanisms of MP action in demyelinating diseases and SCI (Schmidt et al., 2000; Xu et al.,
2001a; Tsutsui et al., 2008). However, GC or antioxidant therapies were ineffective in gray matter injuries, such as head
trauma or stroke (Edwards et al., 2005; Diener et al., 2008).
The mechanism underlying preferential effects of GCs in the
white, but not gray, matter remains to be defined.
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MP upregulates antiapoptotic Bcl-xL gene expression to protect OLGs against AMPA-induced death in vitro and in a rat SCI
model in vivo (Lee et al., 2008). Bcl-xL expression is also upregulated by erythropoietin (Epo)/Epo receptor (Silva et al., 1999).
Epo is effective in animal models of SCI and MS (Gorio et al.,
2002; Li et al., 2004). Epo upregulation involves activation of
hypoxia-inducible factor-1␣ (HIF-1␣) (Semenza et al., 1991; Liu
et al., 2005), a member of the PAS (PER/ARNT/SIM) family of
basic helix–loop– helix (bHLH) transcription factors essential in
hypoxia sensing for cell survival (Sharp and Bernaudin, 2004;
Semenza, 2009). During activation, HIF-1␣ translocates into the
nucleus and heterodimerizes with aryl hydrocarbon receptor nuclear translocator (ARNT), also known as HIF-1␤, to bind to
hypoxia-responsive elements (HRE) in the 3⬘ enhancer of the Epo
gene to induce Epo expression (Semenza et al., 1991).
We report here Epo transactivation involving GR and HIF-1␣
interaction is a causal mechanism of MP protection of OLGs, but
not neurons, against AMPA excitotoxicity. These findings offer
novel insights into the development of innovative therapies for
white matter diseases.

Materials and Methods
Animals. Sprague Dawley rats were obtained from the National Institute
of Experimental Animal Research (Taipei, Taiwan). Animals were killed
by an overdose of sevoflurane to minimize pain or discomfort. All animal
experimentation procedures were approved by the Experimental Animal
Review Committee at Taipei Medical University and are in accordance
with the National Institutes of Health Guide for the Care and Use of
Laboratory Animals.
Cell cultures. OLGs in culture were prepared from postnatal day 0 –2
neonatal rat brains (Xu et al., 2001b; Lee et al., 2004). OLG purity was
⬎90% based on receptor interacting protein (RIP) immunoreactivity
(Xu et al., 2001b; Lee et al., 2004). Cortical neurons were prepared from
fetal rat brains at embryonic day 17 as described previously with ⬃85%
cells in culture expressing the neuronal marker MAP-2 (Lee et al., 2008).
Cortical neurons at 10 d in vitro (DIV) that express GR were used in this
study.
Quantitative real-time and semiquantitative reverse transcription-PCR.
Total RNA extraction, cDNA preparation, and reverse transcription (RT)-PCR
were as described previously (Lee et al., 2008). The real-time PCR reaction
was performed using an ABI PRISM 7300 Sequence Detection System. The
semiquantitative PCR of Epo, Nr3c1 (GR), Hif1a (HIF-1␣), Arnt (HIF-1␤),
and Bcl-xL cDNAs was performed using the following primers, and cDNA of
a reference gene Gapdh (glyceraldehyde-3-phosphate dehydrogenase) was
measured in parallel as an internal control: Epo, 5⬘-TGCGACAGTCGCGTTCTGGAGAGGTAC-3⬘ and 5⬘-ATCCGCTGTGAGTGTTCGGAGTGGAGC-3⬘;Nr3c1(GR),5⬘-AGAATGTCTCTACCCTGCATGTATGAC-3⬘and
5⬘-CTGGAAGCAGTAGGTAAGGAGATTCTC-3⬘; Hif1a (HIF-1␣), 5⬘-CAAGATCAGCCAGCAAGTCCTTCTGATG-3⬘ and 5⬘-AGGTTTCTGTAACTGGGTCTGCTGGAATC-3⬘; Arnt (HIF-1␤) 5⬘-CTGTTGTCCAGAGGGCTATTAAG-3⬘ and 5⬘-CAAGTCTCTCTTTATCGGCAGAG-3⬘; Bcl-xL,
5⬘-AGGCTGGCGATGAGTTTGAA-3⬘ and 5⬘-TGAAACGCTCCTGGCCTTTC-3⬘; and Gapdh, 5⬘- GACCCCTTCATTGACCTCAAC-3⬘ and 5⬘GATGACCTTGCCCACAGCCTT-3⬘.
SCI animal model. SCI was conducted using a New York University
Impactor (Hashimoto et al., 2007) to injure rat spinal cord at T9 –T10
(Lee et al., 2008). Sprague Dawley rats (9 weeks old) were randomly
divided into three groups: the sham control, SCI, and SCI with MP
treatment groups. Vehicle or MP (30 mg/kg body weight) was administered intravenously 30 min after SCI. Four and 24 h after treatment,
animals were anesthetized, and a 1 cm segment of the injured cord centering at the injury epicenter or corresponding sham-operated cord tissue was collected for quantitative real-time RT-PCR analysis.
Western blot analysis. Western blot analysis was performed as described previously (Xu et al., 2001b; Lee et al., 2008). Primary antibodies
used were rabbit anti-Bcl-xL (1:500; Santa Cruz Biotechnology), rabbit
anti-GR (1:500; Santa Cruz Biotechnology), mouse anti-HIF-1␣ (1:500;
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Novus), mouse anti-HIF-1␤ (1:1000; Millipore Bioscience Research Reagents), and mouse anti-GAPDH (1:5000; Biogenesis) antibodies. The
immune complex was visualized using HRP-reactive ECL reagents (GE
Healthcare).
RNA knockdown. OLGs were transfected with a set of siRNAs specific for
GR, HIF-1␣, HIF-1␤, Epo, or scrambled RNA (Silencer Predesigned siRNA;
Ambion) using Lipofectamine reagent (Invitrogen). The siRNA sequences
were as follows: GR (Nr3c1; GenBank accession number NM_012576), 5⬘GGUUGCUUAAAGAAAGUUtt-3⬘ (exon 9) and 5⬘-GCUACAGUCAAGGUUUCUGtt-3⬘ (exon 1); HIF-1␣ (Hif1a; GenBank accession number
NM_024359), 5⬘-GCUUGCUCAUCAGUUGCCAtt-3 (exon 2) and 5⬘CCAGUUGAAUCUUCAGAUtt-3⬘ (exon 9); HIF-1␤ (Arnt; GenBank accession number NM_012780), 5⬘-GGCUGGAUUUUGAUGAUGAtt-3⬘
(exon 2) and 5⬘-CGGCCUACAUUGUCUAACAtt-3⬘ (exon 15); and Epo
(GenBank accession number NM_017001), 5⬘-GGAGGCAGAAAAUGUCACAtt-3⬘ (exon 2) and 5⬘-GGCUGUAGAAGUUUGGCAAtt-3⬘ (exon 4).
Five hours after transfection, the Lipofectamine-containing medium was
replaced with OLG culture medium to allow cells to recover for another 67 h.
Luciferase activity assay. Three copies of human EPO gene enhancer
(HREEPO)-containing sequences, 5⬘-ATAGGTACCGCCCTACGTGCTGTCTCAGCCCTACGTGCTGTCTCAGCCCTACGTGCTGTCTCAGCTAGCTAT-3⬘, were cloned into promoter of pGL2 promoter vector
(Promega) to obtain the luciferase reporter construct pHREEPO–Luc.
The cells were transfected with pHREEPO–Luc and pRL–TK (Promega)
in Lipofectamine for 36 h, followed by treatments with various agents for
24 h, and then harvested for the luciferase activity assay using the DualLuciferase reporter assay system (Promega).
Coimmunoprecipitation. Nuclear fraction of OLGs was extracted using
NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce). Nuclear
proteins (50 g) were incubated with mouse anti-GR antibody (2 g;
Abcam) or mouse anti-HIF-1␣ antibody (2 g; Novus) for 12 h at 4°C,
followed with protein G Sepharose for 1 h at 25°C. The immune complex
was then washed and dissociated according to the Protein G Sepharose 4
Fast Flow protocol (GE Healthcare). Dissociated immune complex was
then subjected to Western blotting using rabbit anti-GR (1:500; Santa
Cruz Biotechnology), mouse anti-HIF-1␣ (1:500; Novus), and mouse
anti-HIF-1␤ (1:500; Millipore Bioscience Research Reagents) antibodies,
respectively.
Yeast two-hybrid assay. Yeast two-hybrid assay was performed as described previously with minor modifications (Wang et al., 2004). The
plasmid pGBKT7–mHIF-1␣ PAS-B was constructed by cloning a PAS
domain (amino acids 238-346) of HIF-1␣ into pGBKT7 (Clontech).
pGADT7–GR–DNA binding domain (DBD) (amino acids 436-516) and
pGADT7–GR–ligand binding domain (LBD) (amino acids 601-751)
were cloned by inserting DNA fragments of GR derived from pcDNA3.1–
rGR (pcDNA3.1–rGR kindly provided by Dr. Trevor K. Archer, LMC,
National Institute of Environmental Health Sciences, National Institutes
of Health, Research Triangle Park, NC) between the NdeI and XhoI sites
of pGADT7 (Clontech). Y190 cells were cotransformed with GAL4AD–
GR–DBD (pGADT7–GR–DBD) and GAL4BD–HIF-1␣ PAS-A
(pGBKT7–HIF-1␣ PAS-A) or with GAL4AD–GR–LBD (pGADT7–GR–
LBD) and GAL4BD–HIF-1␣ PAS-B (pGBKT7–HIF-1␣ PAS-B) based
plasmids. The transformed cells were plated onto a 25 mM 3-amino1,2,4-triazole (3-AT) containing SD medium (Synthetic Dropout)
lacking tryptophan, histidine, and leucine. Five independent colonies
were inoculated to examine ␤-galactosidase activity using o-nitrophenyl␤-D-galactopyranoside as the substrate with A420nm measured in the
liquid culture assay. The ␤-galactosidase unit was calculated by the following equation: ␤-galactosidase units ⫽ 1000 ⫻ A420/(t ⫻ V ⫻ A600),
where t is elapsed time (minutes) of incubation, V is 0.1 ml ⫻ concentration factor, and A600 the density of yeast culture.
Chromatin immunoprecipitation assay (Lin et al., 2008). Antibodies
used for immunoprecipitation were mouse anti-GR (2 g; Abcam),
mouse anti-HIF-1␣ (2 g; Novus), and rabbit anti-CREB (cAMP response element-binding) protein binding protein (CBP) (2 g; Santa
Cruz Biotechnology) antibodies. Immune complex-bound DNA was
purified using a PCR purification kit (Qiagen) and amplified by quantitative PCR (Applied Biosystems) with primers flanking an HREcontaining Epo gene 3⬘ enhancer fragment: (⫹3497 to ⫹3618; GenBank
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accession number NM_017001) 5⬘-TACCTCCCCCCCCCCCCATTCTGGT-3⬘ and 5⬘-CAAGCCCAGAGGGGTCAAGAGGTCAGA-3⬘.
Primers flanking an Epo gene promoter fragment (⫺375 to ⫺221;
GenBank accession number NM_017001) were 5⬘-CAGCCTGCTCTACCCCAGCAAGGA-3⬘ and 5⬘-GGGGGTCGGGGATGTTATCAGCA-3⬘.
Primers flanking a GRE-containing Trh (thyrotropin releasing hormone) gene promoter fragment (⫺267 to ⫺71; GenBank accession
number NM_013046) were 5⬘-CGCGGACTACTCCCGGGACGTCTCT-3⬘ and 5⬘-GGGGAGGGGGCGCAGGCCGAAGACA-3⬘. Normal
mouse IgG served as the control.
Computer modeling of protein–protein interaction. The structures of GR
and HIF-1␣ were obtained as described below for the predictive structural analysis of GR–HIF-1␣ interaction. For GR, the structure of GR–
DBD (amino acids 439-510) is available [Protein Data Bank (PDB)
identification number 1GDC], and GR–LBD (amino acids 519-795) was
generated by SWISS-MODEL Repository (Schwede et al., 2003) using the
protein template PDB identification numbers 1 NHZ, 1M2Z, and 1P93.
No crystal structure information of HIF-1␣ is available. We used conserved domain search of National Center for Biotechnology Information
BLASTp (protein–protein basic local alignment search tool) for sequence
domain analysis. The PAS-B domain of HIF-1␣ was predicted by sequence homology (PDB identification numbers 1P97, A24A, A24B,
1XO0, and 1WA9). Furthermore, fold recognition and threedimensional annotation were conducted to obtain a predicted threedimensional structure. Prediction of interactions of the GR–DBD and
GR–LBD with the PAS-B domain of the HIF-1␣ was then performed
using the program GRAMM (Vakser, 1996). In addition, we predicted
the interaction of HIF-1␣ and HIF-1␤ using the crystal structures of
HIF-2␣–ARNT PAS-B domain complex (PDB identification number
2A24) as a template, followed by predicting the interaction of GR–DBD
and GR–LBD with the HIF-1␣–HIF-1␤ complex. Finally, the DNA binding capability of GR–DBD in docking into the HIF-1␣ or HIF-1␣–
HIF-1␤ complex was predicted.
Statistic analysis. Data were expressed as means ⫾ SEM. Statistical
analysis was performed by one-way ANOVA, followed by Newman–
Keuls multiple comparison post hoc test to compare all groups with the
control group or to compare designated pairs of groups. p ⬍ 0.05 was
considered significant.

Results
MP upregulation of Epo expression in OLGs but not
cortical neurons
We noted in a recent study that neuroprotective effect of MP is
restricted to OLGs, but not neurons, in the injured spinal cord
(Lee et al., 2008). MP or other GCs are effective in treating white
(Zivadinov et al., 2001; Chataway et al., 2006), but not gray (Edwards et al., 2005; Diener et al., 2008), matter diseases. Epo has
similar effects in SCI (Gorio et al., 2002; Vitellaro-Zuccarello et
al., 2007) and the white matter diseases (Li et al., 2004). These
findings suggest MP and Epo may share a common neuroprotective mechanism. Figure 1 A shows that MP upregulated Epo
mRNA expression in OLGs, but not neurons, based on semiquantitative (top panel) and quantitative (bottom panel) RTPCR analysis. Epo transactivation has been shown to involve
HIF-1␣, a cytoprotective transcription factor, inducible by hypoxia (Semenza et al., 1991; Sharp and Bernaudin, 2004; Semenza,
2009). Cobalt chloride (CoCl2) activates HIF-1␣, mimicking
hypoxia. Whereas MP failed to upregulate Epo expression in neurons, chemical hypoxia induced by CoCl2 was effective in neurons as well as OLGs (Fig. 1 A, top panel). This finding suggests
that neuronal cultures used in the present study maintain a
hypoxia-inducible response for upregulating Epo expression but
do not share MP responsiveness noted in OLGs. The ELISA results show that MP increased the Epo protein content in OLGs in
a dose-dependent manner with an EC50 of 83.11 nM (Fig. 1 B).

Figure 1. MP upregulation of Epo expression in OLGs and injured spinal cord but not neurons. A, OLGs and 10 DIV cortical neurons were treated with MP (1 M) or CoCl2 (0.4 mM) for 12 h,
followed by RNA extraction. Epo mRNA was analyzed by semiquantitative (top) and quantitative real-time (bottom) RT-PCR, in which Gapdh and ␤-actin mRNA served as internal controls,
respectively. B, Dose–response effect of MP in inducing Epo expression in OLGs was measured
by ELISA at 24 h. C, MP (30 mg/kg body weight, i.v.) was given 30 min after SCI. The spinal cord
tissues harvested 4 and 24 h after SCI were subjected to quantitative real-time RT-PCR for
assessing the extent of Epo mRNA expression. The Ct value was normalized and expressed
relative to the sham-operated control (Sham). Data are expressed as means ⫾ SEM (n ⫽ 4 in A
and B; n ⫽ 5 in C). *p ⬍ 0.05, **p ⬍ 0.01 versus the control (Ctrl) (A), the 0 M MP group (B),
or the SCI group (C) by one-way ANOVA and Newman–Keuls multiple comparison post hoc test.

MP upregulation of Epo expression in the injured spinal cord
in vivo
We further examined whether MP treatment affects Epo gene
expression in the injured spinal cord in rats. Figure 1C shows MP
upregulation of Epo mRNA expression in the spinal cord 4 and
24 h after injury with a dosing schedule (intravenous MP, 30
mg/kg body weight given 30 min after insult) that has been shown
to reduce the extent of OLG apoptosis and white matter damage
after SCI (Lee et al., 2008). Results suggest that MP-induced Epo
expression occurs not only in cultured OLGs in vitro but also in
the injured spinal cord in vivo.
Causal role of Epo expression in MP protection of OLGs
against excitotoxicity
To establish the causal role of Epo expression in MP protection of
OLGs against excitotoxicity, we first studied whether exogenous
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Epo shares a similar cytoprotective action
as MP in OLGs. Both EPO (Silva et al.,
1999) and MP (Xu et al., 2009) engage the
JAK/STAT5 pathway in upregulating BclxL, an antiapoptotic gene. Both human recombinant EPO (rhEPO, 40 ng/ml) and
MP upregulated Bcl-xL expression in
AMPA-treated OLGs (Fig. 2 A), sharing a
common cytoprotective mechanism. Application of rhEPO also protected OLGs
against AMPA-induced death (Fig. 2 B).
To confirm the causal role of Epo expression in MP protection of OLGs, we applied Epo small interfering (si) RNA
(siEpo) to knockdown Epo expression
(Fig. 2C, inset). The cytoprotective action
of MP was abolished in OLGs transfected
with siEpo but not scrambled RNA (Fig.
2C). These findings support the contention that Epo expression is causally related
to MP protection of OLGs against AMPA
excitotoxicity.
GR-dependent activation of HIF-1␣
by MP
Transactivation of Epo gene entails the activation of HIF-1␣ to bind to HRE in the
3⬘ Epo enhancer region (Semenza et al.,
1991). Therefore, we examined whether
MP upregulation of Epo expression is mediated by HIF-1␣ activation. We established a luciferase reporter construct by Figure 2. Epo and MP in AMPA-induced OLG death. A, OLGs were treated with AMPA (100 M) supplemented with cyclothiainserting an HRE-containing DNA frag- zide (25 M) (referred to as AMPA hereafter) with rhEPO (4 U/ml, 40 ng/ml) (left) or MP (right) for 24 h, followed by Western
ment of the Epo gene enhancer into a blotting for Bcl-xL. B, rhEPO effect on OLG viability after AMPA treatment based on MTT assay. C, Epo mRNA expression after OLG
pGL2-promoter vector (pHREEPO–Luc) transfection with scrambled RNA (Scr) or siRNA specific for rat Epo mRNA (siEpo) (top). Effects of Scr or siEpo transfection on MP
to study the effect of MP on Epo expres- protection of OLGs against AMPA cytotoxicity (bottom). *p ⬍ 0.05, **p ⬍ 0.01 versus the control group; #p ⬍ 0.05 versus the
sion in relation to HIF-1␣ activity. AMPA-treated group. NS, No significant difference between the two groups (n ⫽ 4).
Treatment with 1 M MP increased
indeed reduces HIF-1␣ at the protein level, we used a strategy
HREEPO-driven luciferase activity in OLGs but not neurons
reported previously (Siddiq et al., 2009) to confirm the knock(Fig. 3A), whereas chemical hypoxia (CoCl2) induced a similar
down efficiency of siHIF1a in hypoxia-treated OLGs (suppledegree of HREEPO-driven luciferase activity in both cell types
mental Fig. 1C, available at www.jneurosci.org as supplemental
(Fig. 3B), confirming that this expression construct is responsive
material). GR or HIF-1␣ knockdown abolished MP activation of
to an established HIF-1␣ activation mechanism. Figure 3C shows
pHREEPO–Luc (Fig. 4 A), MP upregulation of Epo (Fig. 4 B) and
that dexamethasone, a potent GR agonist, increased HREEPOBcl-xL (Fig. 4C), and the protective effect of MP against AMPAdriven luciferase activity, comparable with MP. Non-GC steinduced cell death in OLGs (Fig. 4 D). HIF-1␣ knockdown even
roids, such as aldosterone, a mineralocorticoid receptor (MR)
accentuated AMPA excitotoxicity (Fig. 4 D). These results supagonist, or 17␤-estradiol, an estrogen receptor agonist, were
port the causal role of GR and HIF-1␣ in mediating the cytoprowithout effects. GR-dependent action of MP was further contective action of MP via upregulation of Epo expression in OLGs.
firmed by the findings that RU486 [11␤-[p-(dimethylamino)
phenyl]-17␤-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one] (a
MP enhancement of nuclear GR–HIF-1␣ interaction in OLGs
GR antagonist), but not spironolactone (an MR antagonist), was
GR may regulate gene expression by interacting with other traneffective in blocking MP activation of HIF-1␣ at the basal level
scription factors (Xu et al., 2009). We explored whether GR in(Fig. 3D) or after AMPA treatment (Fig. 3E).
teracts with HIF-1␣ directly in MP transactivation of Epo gene
expression. The blotting pattern of HIF-1␣, verified by CoCl2
Reversal of MP activation of pHREEPO–Luc and upregulation of
(supplemental Fig. 1C, available at www.jneurosci.org as suppleEpo expression by GR or HIF-1␣ knockdown
mental material), was used to identify HIF-1␣ in the coimmunoTo confirm the causal role of GR and HIF-1␣ in Epo expression
precipitation (co-IP) study. MP treatment increased nuclear
and subsequent Bcl-xL upregulation by MP, we transfected OLGs
HIF-1␣ accumulation in OLGs but not neurons (Fig. 5A). The
with specific siRNAs against Nr3c1 (siGR) or Hif1a (siHif1a) to
GR content in the nuclear fraction was increased in OLGs as well
knockdown GR and HIF-1␣ expression, respectively. Both
as neurons after MP treatment (Fig. 5B). However, an increase in
mRNA and protein levels of GR and HIF-1␣ were reduced by
GR–HIF-1␣ interaction after MP treatment was noted only in
their specific siRNA (supplemental Fig. 1 A, B, available at www.
OLGs but not neurons when immunoprecipitating the nuclear
jneurosci.org as supplemental material). To verify that siHif1a
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Figure 3. MP effect on HREEPO-driven luciferase activity in OLGs. OLGs or neurons were cotransfected with pHREEPO–Luc and
pRL–TK for 36 h before the respective treatments, followed by the luciferase activity assay. A, OLGs and neurons were with or
without MP (1 M) treatment for 24 h. B, OLGs and neurons were treated with CoCl2 (0.4 mM) for 24 h. Note that both OLGs and
neurons are responsive to chemical hypoxia induced by CoCl2. C, OLGs were treated with steroids, including MP, dexamethasone
(Dex), aldosterone (Ald), and 17-␤-estradiol (E2), 1 M each for 24 h. D, OLGs were pretreated with 1 M RU486 (RU; a GR
antagonist) or spironolactone (SP; an MR antagonist) for 30 min, followed by MP (1 M) for 24 h. E, OLGs were pretreated with RU486
(1 M) for 30 min, followed by AMPA with or without MP. **p ⬍ 0.01 versus vehicle-treated control (Ctrl) (n ⫽ 4).
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blotting with a GR antibody (see Fig. 7B).
This result is in agreement with previous
findings that MP transactivates Epo expression only in OLGs but not neurons.
Co-IP of two proteins can result from
either direct or indirect interaction. We
conducted yeast two-hybrid analysis to
explore possible direct interaction between GR and HIF-1␣. Based on the domain maps of GR and HIF-1␣ (Fig. 5C),
we examined the interactions between
GR–LBD and GR–DBD, respectively,
with the HIF-1␣ PAS-A (amino acids 85153) and PAS-B (amino acids 238-346)
domains. The GR–DBD, but not the GR–
LBD, yielded appreciable number of colonies when hybridized with the HIF-1␣
PAS-A or PAS-B domain (Fig. 5D). Results suggest that the GR–DBD, but not
the GR–LBD, directly interacts with the
HIF-1␣ PAS domains.

Co-recruitment of HIF-1␣ and GR onto
the promoter and 3ⴕ enhancer of the
Epo gene in OLGs but not neurons
Because MP induces GR–HIF-1␣ interaction (Fig. 5), we examined whether the
GR–HIF-1␣ complex is recruited to the
promoter or/and 3⬘ enhancer of the Epo
gene during MP treatment. Chromatin
immunoprecipitation (ChIP) analysis
was performed by immunoprecipitating
nuclear HIF-1␣ or GR, followed by PCR
amplification of promoter fragments
spanning from ⫺375 to ⫺221 and HREcontaining 3⬘ enhancer fragments spanning from ⫹3497 to ⫹3618 of the Epo
gene, respectively (Fig. 6 A). Preferential
effects of MP on the GR–HIF-1␣ association with the Epo promoter and enhancer
were observed in OLGs (Fig. 6 B) compared with neurons (Fig. 6C). In OLGs
but not neurons, the association of
HIF-1␣ and GR to the Epo promoter was
increased to threefold at 1 and 3 h after
MP treatment (Fig. 6 B). Interestingly, GR
and HIF-1␣ binding to the 3⬘ enhancer
was not significant until 3 h after MP
treatment, when ⬃2.5-fold and 7-fold increase was noticed compared with basal
binding activity (0 h), respectively. In
neurons, HIF-1␣ had a slight and tranFigure 4. HIF-1␣ and GR knockdown on MP-induced HREEPO enhancer activity and Epo/Bcl-xL expression. OLGs were trans- sient association with the Epo enhancer
fected with scrambled siRNA (Scr), siNr3c1 (for GR), or siHif1a (for HIF-1␣) for 72 h, followed by: A, transfection with pHREEPO–Luc after MP treatment. No significant associfor 24 h and then MP (1 M) treatment for 24 h, followed by luciferase activity assay; B, quantitative real-time RT-PCR analysis of ation of HIF-1␣ with the promoter was
Epo mRNA; C, semiquantitative RT-PCR analysis of Bcl-xL mRNA; D, AMPA treatment with or without MP (1 M) for 24 h for cell observed in neurons. More importantly,
death analysis by LDH release assay. *p ⬍ 0.05, **p ⬍ 0.01 versus vehicle-treated control (Ctrl); #p ⬍ 0.05 versus the AMPA- no significant GR binding to either the
treated group (n ⫽ 4).
promoter or 3⬘ enhancer was noted in
neurons (Fig. 6C). As a positive control,
protein extracted from the MP-treated cells with a GR antibody
MP-induced GR binding to a GRE-containing fragment in the
and blotting with an HIF-1␣ antibody (Fig. 5B). The MPpromoter of Trh, an established GC-responsive gene, was examincreased GR–HIF-1␣ interaction in OLGs was further verified
ined in both OLGs and neurons. As shown in Figure 6 D, MP
by using immunoprecipitation with an HIF-1␣ antibody and
induced GR binding to GRE to a similar extent in both cell
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types. These findings suggest that corecruitment of HIF-1␣ and GR to the Epo
promoter/enhancer occurs in OLGs but
not in neurons. The association of GR and
HIF-1␣ with the Epo promoter and enhancer in OLGs appears sequential, occurring at 1 and 3 h, respectively, after MP
treatment.
The transcriptional activation of Epo
gene by HIF-1␣ requires a DNA looping
mechanism that brings the HIF-1␣/HIF1␤-bound 3⬘ enhancer to contact the promoter of Epo gene by interacting with
CBP/p300 (Ebert and Bunn, 1998), which
serves as a coadaptor to activate an RNA
polymerase II-containing general transcription factor complex to initiate gene
transcription (von Mikecz et al., 2000).
We conducted anti-CBP antibody-based
ChIP assay to examine whether MP treatment recruits CBP/p300 to the Epo promoter in OLGs and neurons. Figure 6 E
shows that CBP association with the Epo
promoter was increased by approximately
sixfold after MP treatment for 1 h in OLGs
but not neurons, when HIF-1␣ and GR
were detected in the same promoter region
(Fig. 6B). This finding suggests that MPinduced HIF-1␣–GR association with the
Epo gene promoter is accompanied by the
recruitment of CBP/p300 to the promoter
to trigger Epo gene transcription.

Figure 5. MP activation of GR–HIF-1␣ interaction in OLGs but not neurons. A, Immunoblotting of nuclear HIF-1␣ with or
without MP treatment in OLGs and neurons. B, Nuclear fractions of OLGs and neurons were immunoprecipitated with an anti-GR
antibody (IP-GR) and Western blotted with an anti-HIF-1␣ or anti-GR antibodies. IgG served as the loading control for the
immunoprecipitated complex for quantitative analysis of band intensity. The right shows composite results. **p ⬍ 0.01 versus the
control (0 min) group, n ⫽ 3. C, Domain maps of GR and HIF-1␣. Major domains of GR include AF-1 activation domain, DBD and
LBD; major domains of HIF-1␣ include bHLH, PAS-A, PAS-B, and oxygen-dependent degradation (ODD) domain. The shaded
domains in gray were used for yeast two-hybrid analysis and computer modeling for protein–protein docking. D, Yeast two-hybrid
analysis of GR–HIF-1␣ interaction. Left, GAL4-activation domain (GAL4AD, amino acids 768-881) hybrid and GAL4 –DNA-binding
domain (GAL4BD, amino acids 1-147) hybrid. Right, Yeast colony numbers after transformation and ␤-galactosidase activity (n ⫽
5). N.D., Not detectable.

HIF-1␤ association with GR–HIF-1␣
complex is required for the Epo induction by MP treatment
MP-induced GR–HIF-1␣ binding to the 3⬘ enhancer of Epo gene
correlated well with its activation of HREEpo–Luc, each requiring
binding of both HIF-1␣ and HIF-1␤ (Jiang et al., 1996). Knockdown of HIF-1␤ using a specific siRNA (supplemental Fig. 1 A,
available at www.jneurosci.org as supplemental material) suppressed Epo expression induced by MP or CoCl2 (Fig. 7A).
Furthermore, the co-IP results show that MP significantly increased HIF-1␤ content to the HIF-1␣-immunoprecipitated
complex to a similar degree as GR (Fig. 7B). Together, these
results suggest that recruitment of HIF-1␤ to the GR–HIF-1␣
complex is required for MP transactivation of Epo expression.
Structural analysis of interactions among GR, HIF-1␣,
HIF-1␤, and DNA
To understand the interaction of the HIF-1␣ PAS domain with
the GR–DBD and their relationship with the interaction of
HIF-1␣ and HIF-1␤, which is required for HIF-1␣ binding to
HRE, we applied a computational modeling approach to perform
a structural analysis of protein–protein interactions among GR,
HIF-1␣, and HIF-1␤. The structures of the GR–DBD and GR–
LBD were retrieved from protein data banks (PDB identification
numbers 1GDC and 1NHZ, respectively), whereas those of
HIF-1␣ were predicted by homology to obtain a structure for the
PAS-B domain at amino acids 238-346. Based on thermal dynamics and intermolecular distances, the modeling results show
that the GR–DBD binds HIF-1␣ on the PAS-B domain while
retaining its DNA binding activity (Fig. 8 A). Furthermore, the
seven residues of the GR–DBD (Gly470, His472, Tyr497, Arg498,

Gln502, Asn506, and Glu508) interact with Tyr277, Asp250,
Leu249, Glu334, Asn330, Thr297, and Asp294 of the HIF-1␣
PAS-B domain, respectively. We modeled the structure of the HIF1␣–HIF-1␤ complex (Fig. 8B) to explore its possible interactions
with the GR–DBD. Figure 8C shows that the HIF-1␣ PAS-B complex interacts with the GR–DBD and HIF-1␤ simultaneously, preserving the DNA binding activity of the GR–DBD. Results from the
protein docking analysis are summarized in Figure 8D.

Discussion
Results from the present study are the first to demonstrate that
MP protects OLGs against excitotoxicity via the HIF-1␣/Epo/
Bcl-xL cascade in a cell-type-specific manner under normoxic
condition. Several lines of experimental evidence support a
causal role of this cascade in MP protection against AMPAinduced excitotoxicity in OLGs. First, exogenous Epo is effective
in protecting OLGs against AMPA-induced OLG death. Second,
both MP and Epo share a similar cytoprotective mechanism by
upregulating Bcl-xL expression in AMPA-treated OLGs. Third,
MP transactivates Epo expression in a GR-, HIF-1␣-, and HIF1␤-dependent manner. Fourth, the causal roles of GR, HIF-1␣,
and Epo are substantiated by the findings that knockdown of GR,
HIF-1␣, or Epo expression abolishes the cytoprotective action of
MP in OLGs. Finally, MP activation of HIF-1␣ occurs in a GRdependent manner involving stabilization of HIF-1␣ and complex GR–HIF-1␣ interaction as supported by pHREEPO–Luc
studies, co-IP, ChIP assays, the yeast two-hybrid analysis, and
computer modeling of protein–protein interactions.
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(factor inhibiting HIF) playing an important role. It remains to be determined
whether these factors are involved in the GR
activation of HIF-1␣.
In contrast to the GR–HIF-1␣
crosstalk under hypoxic condition in
COS7 cells engaging GR–LBD (Kodama
et al., 2003), the present study reveals an
essential role of GR–DBD in the normoxic
mode of GR–HIF-1␣ interaction. In addition, the binding activity of the GR–DBD
to GRE in the GR–HIF-1␣–HIF-1␤ complex is preserved according to the molecular modeling results (Fig. 8 A, C) that are
in agreement with the finding that mutation of single amino acid (A458T) essential for the DNA binding activity of GR
failed to interrupt GR activation of HIF-1␣
under hypoxia condition (Kodama et al.,
2003). However, we noted another seven
amino acid residues of the GR–DBD
interacting with seven corresponding
amino acid residues in the HIF-1␣ PAS-B
domain. This finding raises the possibility
that different binding domains (the GR–
LBD under hypoxia vs the GR–DBD under normoxia) may be separately engaged
Figure 6. MP recruitment of HIF-1␣ and GR onto the Epo promoter and 3⬘ enhancer in OLGs but not neurons. A, Schematic depending on oxygen tension. Additional
representation of the rat Epo gene promoter and enhancer. The Epo enhancer contains an HIF-1␣ binding site (HRE). OLGs and
studies are needed to differentiate GR–
neurons were treated with MP (1 M) for 0, 1, and 3 h, followed by ChIP assay for the GR- and HIF-1␣–Epo promoter and enhancer
in OLGs (B) and neurons (C). ChIP assay of untreated cells with normal IgG served as a negative control in each set of experiments. HIF-1␣ interactions under oxygenD, ChIP assay of the GRE-containing Trh gene promoter fragment (GRETrh) served as a GR activation control. E, OLGs and neurons independent versus oxygen-dependent
were treated with MP (1 M) for 0, 1, and 3 h, followed by ChIP assay for the CBP–Epo promoter. *p ⬍ 0.05, **p ⬍ 0.01 versus the paradigms involving the GR–DBD or
GR–LBD, respectively.
respective group without MP treatment; n ⫽ 4.
Cell-type-specific activation of HIF-1␣
in oligodendrocytes, but not neurons, is
HIF-1␣, as its name implies, is induced by hypoxia. Hypoxia
another novel finding in the present study. The mechanism of
does upregulate Epo expression in both OLGs and neurons.
this differential action of MP remains to be fully elucidated. FigHowever, MP upregulation of Epo and activation of HIF-1␣ are
ures 5 (A and B) and 6 (B, C, and E) suggest that the critical
selective for OLGs but not neurons under normoxic condition.
signaling event that differentiates oligodendrocytes from neuTo the best of our knowledge, this is the first report on activation
rons in responding to MP is the association of GR with HIF-1␣,
of HIF-1␣ under normoxic condition by a therapeutic agent MP.
which occurs in oligodendrocytes but not neurons. MP activaHIF-1␣ was increased in MP-treated OLGs (30 min) (Fig. 5A)
tion of GR is a universal event in all the GR-expressing cell types,
before the increase of GR–HIF-1␣ interaction (60 min) (Fig. 5B),
including OLGs and neurons, as demonstrated in Figure 5B.
suggesting that MP-activated GR induces HIF-1␣ activity via
However, MP does not increase HIF-1␣ in neurons (Fig. 5A),
both stabilization of and interaction with HIF-1␣. It is noted that,
which matches well with the co-IP results that GR–HIF-1␣ interafter MP treatment in OLGs for 30 min, both HIF-1␣ accumulaaction is not increased in neurons (Fig. 5B, right panel). Figure
tion (Fig. 5A) and GR activation (Fig. 5B, right top panel) occur,
6 B–D also shows that the differential transcriptional events
but the GR–HIF-1␣ interaction was not apparent until 60 min
in response to MP are gene specific with Trh, a typical
(Fig. 5B). Lack of an increase in GR–HIF-1␣ interaction at the
glucocorticoid-responsive gene, responding to MP in both neu30 min time point reflects the time lag for activated GR to
rons and oligodendrocytes, in contrast to Epo, responsive to MP
interact with HIF-1␣. The sequence of events leading to interonly in oligodendrocytes but not neurons. The molecular mechaction of GR and HIF-1␣ entails the recruitment of GR and
anism leading to the divergence in interaction between two tranHIF-1␣ to form a protein complex as depicted in Figure 8.
scription factors should be an important topic in future studies.
More importantly, this mechanism well explains the MP proFurthermore, this cell-type-specific effect of MP is reflected by
tection of OLGs, but not neurons, against AMPA excitotoxicpreferential co-recruitment processes of HIF-1␣ and GR onto the
ity as shown in our previous studies (Lee et al., 2008). In the
Epo promoter/enhancer and stabilization of HIF-1␣ association
present study, we have established the essential roles of GR,
with the Epo promoter/enhancer in OLGs compared with neuHIF-1␣, and Epo in MP upregulation of Bcl-xL as the underrons (Fig. 6). It is noted that both Epo promoter and 3⬘ enhancer
lying mechanism of MP protection of OLGs against AMPA
regions contain no sequences with appreciable similarity with
toxicity normoxia (Fig. 4C,D). Activation of HIF-1␣ under
GRE (GGTACAnnnTGTTCT), suggesting that the GR–HIF-1␣
normoxia has been demonstrated previously in selected expercomplex is likely to activate the Epo gene via binding to HRE but
imental paradigms (Choi et al., 2006; Liu et al., 2007) with
not GRE. Thus, an apparent increase in GRE binding activity
RACK1 (the receptor for activated C kinase 1) and FIH-1
shown by electrophoretic mobility shift assay may reflect GR
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binding to GRE in the promoter region of
other genes, such as Trh expressed in both
OLGs and neurons, as shown in Figure
6 D, than Epo gene. Importantly, the puzzle of why the GR–HIF-1 complex is recruited to the Epo promoter before its 3⬘
enhancer remains to be unraveled.
One of the interesting features of MP
upregulation of Epo expression is that MP
treatment activates the expression of
HREEpo-driven reporter construct (Fig.
3), which does not contain GRE. Because
activation of HRE requires binding of
both HIF-1␣ and HIF-1␤ (Jiang et al.,
1996), the GR–HIF-1␣ complex will not
bind to HRE unless HIF-1␤ is recruited to
the complex. Our result shows that
HIF-1␤ is recruited to the GR–HIF-1␣
complex during MP treatment, and its expression is essential for the MP-induced
Epo expression (Fig. 7). In addition, ChIP
assay results demonstrated that both GR
and HIF-1␣ are recruited to HREcontaining 3⬘ enhancer of Epo gene at 3 h.
Therefore, these findings converge to
form a conclusion that GR–HIF-1␣–
HIF-1␤ complex binding to HRE is required for the MP activation of HRE–Luc
as well as Epo gene expression. A deduced
model depicted in supplemental Figure 2
(available at www.jneurosci.org as supplemental material) shows that MP induces
interactions among GR, HIF-1␣, and
HIF-1␤, followed by binding to the Epo
gene promoter and 3⬘enhancer along with
the CBP/p300 coadaptor to activate Epo
gene transcription. GR interaction with
HIF-1␣ is the key step in determining the
differential MP effects in OLGs versus
neurons. This novel signaling process
opens a new avenue to treat white matter
diseases by targeting OLGs specifically.
GCs, primarily MP, are the mainstay in
treating diseases affecting the white matter, including MS and SCI. Because of the
very low blood– brain barrier crossing rate
(Chen et al., 1996), large doses of GCs are
needed for treating these diseases. High
doses of GCs frequently lead to serious
side effects, including suppression of immune and adrenal function, loss of connective tissue and bone mass, alteration of
cognitive or mental function, hypertension, glucose intolerance, and others
(McDonough et al., 2008). These side effects prevent administration of MP or
other GCs for extended periods of time to
achieve optimal therapeutic effects. Epo, a
neuroprotective cytokine, has been reported to improve functional recovery in
animal models of demyelinating disorders
(Li et al., 2004) and SCI (Gorio et al.,
2002). However, systemic administration
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Figure 7. HIF-1␤ interaction with the GR–HIF-1␣ complex is required for the MP-induced Epo expression in OLGs. A, OLGs were
transfected with scrambled siRNA (Scr) and siArnt (for HIF-1␤) for 72 h, followed by incubation with MP (1 M) or CoCl2 (0.4 mM)
for 12 h and real-time PCR analysis of Epo mRNA. **p ⬍ 0.01, ***p ⬍ 0.001 versus vehicle-treated control (Ctrl); #p ⬍ 0.05 versus
the MP- or CoCl2-treated group (n ⫽ 3). B, Nuclear fractions of OLGs were immunoprecipitated with an anti-HIF-1␣ antibody
(IP-HIF-1␣) and Western blotted (WB) with an anti-GR or anti-HIF-1␤ antibody. IgG served as the loading control for the immunoprecipitated complex. The right shows composite results. *p ⬍ 0.05 versus control; n ⫽ 3.

Figure 8. Computer modeling of protein–protein interactions among HIF-1␣ PAS-B domain, GR–DBD, and HIF-1␤. A, Predicted structure of HIF-1␣ PAS-B domain docking with the GR–DBD (PDB identification number 1GDC). B, HIF-1␣ PAS-B domain
docking with the HIF-1␤ PAS-B domain. C, GR–DBD docking with the (HIF-1␣ PAS-B)–(HIF-1␤ PAS-B) complex. Insets in A show
predicted amino acid residues for GR–DBD interaction with HIF-1␣ PAS-B. D, Summary of the modeled protein–protein docking results.
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of Epo is also associated with serious side effects, including cardiovascular, hematological, and other disorders (Maiese et al.,
2008). A recent Food and Drug Administration preliminary communication suggests that systemic administration of Epo in patients with acute stroke may be associated with a higher 90 d
mortality, with death related to intracerebral hemorrhage fourfold higher in Epo-treated patients than those in the placebo
group in a clinical trial of Epo. New therapeutic strategies
directed at cell-type-specific upregulation of Epo expression
are preferred to systemic Epo or MP administration.
In conclusion, this is the first demonstration that MP protection of OLGs against excitotoxic death is mediated by the HIF1␣/Epo/Bcl-xL cascade. This MP effect is specific in OLGs, but
not neurons, mainly determined by the cell-type-specific interaction between GR and HIF-1␣. This cell-type-specific signaling
process provides an important insight into advancing therapeutic
strategies for white matter diseases or SCI by OLG-specific transcriptional regulation of Epo expression to avoid serious adverse
side effects associated with currently available therapeutic agents.
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